Science reveals the truth of why you're feeling carsick in EVs
If you've found yourself questioning why you feel a little queasy behind the wheel of the future, don't worry. It's a real thing, and you're not the only one.
According to multiple studies, there are very scientific reasons why a person may experience more motion sickness in an electric vehicle.
Lack of previous experience
Though EVs are becoming increasingly popular, most people's experiences with cars are based on combustion cars.
If you've learnt how to drive in a conventional petrol car, you've likely adapted to their specific cues.
According to a 2020 study published in Applied Ergonomics, the lack of a traditional engine sound could be an influencing factor to motion sickness.
'Being able to anticipate upcoming motion is known to potentially mitigate sickness resulting from provocative motion,' the 2020 study said.
For example, upon pressing the accelerator pedal and hearing the rev of the engine, your brain will prepare you for the increase in speed.
In an electric vehicle, drivers may experience a low hum or even no sound at all, making it harder for their brain to anticipate movement.
'If we are accustomed to travelling in non-EVs, we are used to understanding the car's motion based on signals such as engine revs, engine vibrations, torque, etc,' William Emond, a PhD student at the Université de Technologie de Belfort-Montbéliard in France, explained to The Guardian.
'Yet, travelling in an EV for the first time is a new motion environment for the brain, which needs adaptation,'
Regenerative braking
Similarly, EV's 'regenerative braking' is also a contributing factor to nausea in drivers.
For those unaware, regenerative braking is a system where the vehicle's kinetic energy is generated automatically through the action of braking, and routed back into the battery as usable power.
Regenerative braking can cause motion sickness for EV drivers, especially for those who have the EVs set for max regenerative braking, or for those using one-pedal mode, as the act of simply lifting off the accelerator would cause the car to slow down dramatically.
For drivers, it can feel like the car is slowing down when they haven't prepared for it, and throw off their balance.
'Better knowledge on self-motion allows us to anticipate motion forces, which is crucial for motion sickness,' Emond explained to The Guardian.
'Yet, when the motion forces as estimated or anticipated by the brain differ from what actually is experienced, then the brain interprets this 'neural mismatch' as a situation of conflict.
'If this conflict persists over time, it may surpass a threshold for triggering autonomic reactions of the body such as symptoms apparent to 'motion sickness'.'
For those considering purchasing some new wheels, Australia's car market is undergoing one of its biggest shake-ups in decades, with some experts calling it the most dramatic shift in automotive history.
Australia has become a viable market for Chinese car manufacturers which has lead to aggressive local pricing, especially from brands such as BYD, Chery and GWM.
Carsales.com.au data services Director Ross Booth said much of the automotive growth is coming from electric and electrified vehicles.
'We're seeing a clear shift towards more fuel-efficient vehicles, with strong growth in New Energy Vehicles – which include hybrids, plug-in hybrids, and battery electric vehicles,' Mr Booth said.
Hybrid and electric vehicle sales made up just 8 per cent of new cars in 2021, jumping to 25 per cent by the end of 2025.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Courier-Mail
2 hours ago
- Courier-Mail
Science behind why you're feeling carsick in EVs
Don't miss out on the headlines from New Cars. Followed categories will be added to My News. While electric vehicles are becoming increasingly popular for drivers around the world, many are realising that they can make you more carsick than conventional petrol cars. If you've found yourself questioning why you feel a little queasy behind the wheel of the future, don't worry. It's a real thing, and you're not the only one. According to multiple studies, there are very scientific reasons why a person may experience more motion sickness in an electric vehicle. Lack of previous experience Though EVs are becoming increasingly popular, most people's experiences with cars are based on combustion cars. If you've learnt how to drive in a conventional petrol car, you've likely adapted to their specific cues. According to a 2020 study published in Applied Ergonomics, the lack of a traditional engine sound could be an influencing factor to motion sickness. 'Being able to anticipate upcoming motion is known to potentially mitigate sickness resulting from provocative motion,' the 2020 study said. It's not uncommon to experience nausea in an EV. Picture: iStock For example, upon pressing the accelerator pedal and hearing the rev of the engine, your brain will prepare you for the increase in speed. In an electric vehicle, drivers may experience a low hum or even no sound at all, making it harder for their brain to anticipate movement. 'If we are accustomed to travelling in non-EVs, we are used to understanding the car's motion based on signals such as engine revs, engine vibrations, torque, etc,' William Emond, a PhD student at the Université de Technologie de Belfort-Montbéliard in France, explained to The Guardian. 'Yet, travelling in an EV for the first time is a new motion environment for the brain, which needs adaptation,' Regenerative braking Similarly, EV's 'regenerative braking' is also a contributing factor to nausea in drivers. For those unaware, regenerative braking is a system where the vehicle's kinetic energy is generated automatically through the action of braking, and routed back into the battery as usable power. Regenerative braking can cause EV drivers to feel motion sickness. Picture: iStock Regenerative braking can cause motion sickness for EV drivers, especially for those who have the EVs set for max regenerative braking, or for those using one-pedal mode, as the act of simply lifting off the accelerator would cause the car to slow down dramatically. For drivers, it can feel like the car is slowing down when they haven't prepared for it, and throw off their balance. 'Better knowledge on self-motion allows us to anticipate motion forces, which is crucial for motion sickness,' Emond explained to The Guardian. 'Yet, when the motion forces as estimated or anticipated by the brain differ from what actually is experienced, then the brain interprets this 'neural mismatch' as a situation of conflict. 'If this conflict persists over time, it may surpass a threshold for triggering autonomic reactions of the body such as symptoms apparent to 'motion sickness'.' A carrier vessel transporting EVs globally. Picture: AFP For those considering purchasing some new wheels, Australia's car market is undergoing one of its biggest shake-ups in decades, with some experts calling it the most dramatic shift in automotive history. Australia has become a viable market for Chinese car manufacturers which has lead to aggressive local pricing, especially from brands such as BYD, Chery and GWM. data services Director Ross Booth said much of the automotive growth is coming from electric and electrified vehicles. 'We're seeing a clear shift towards more fuel-efficient vehicles, with strong growth in New Energy Vehicles – which include hybrids, plug-in hybrids, and battery electric vehicles,' Mr Booth said. Hybrid and electric vehicle sales made up just 8 per cent of new cars in 2021, jumping to 25 per cent by the end of 2025. Originally published as Science reveals the truth of why you're feeling carsick in EVs
News.com.au
4 hours ago
- News.com.au
Science reveals the truth of why you're feeling carsick in EVs
While electric vehicles are becoming increasingly popular for drivers around the world, many are realising that they can make you more carsick than conventional petrol cars. If you've found yourself questioning why you feel a little queasy behind the wheel of the future, don't worry. It's a real thing, and you're not the only one. According to multiple studies, there are very scientific reasons why a person may experience more motion sickness in an electric vehicle. Lack of previous experience Though EVs are becoming increasingly popular, most people's experiences with cars are based on combustion cars. If you've learnt how to drive in a conventional petrol car, you've likely adapted to their specific cues. According to a 2020 study published in Applied Ergonomics, the lack of a traditional engine sound could be an influencing factor to motion sickness. 'Being able to anticipate upcoming motion is known to potentially mitigate sickness resulting from provocative motion,' the 2020 study said. For example, upon pressing the accelerator pedal and hearing the rev of the engine, your brain will prepare you for the increase in speed. In an electric vehicle, drivers may experience a low hum or even no sound at all, making it harder for their brain to anticipate movement. 'If we are accustomed to travelling in non-EVs, we are used to understanding the car's motion based on signals such as engine revs, engine vibrations, torque, etc,' William Emond, a PhD student at the Université de Technologie de Belfort-Montbéliard in France, explained to The Guardian. 'Yet, travelling in an EV for the first time is a new motion environment for the brain, which needs adaptation,' Regenerative braking Similarly, EV's 'regenerative braking' is also a contributing factor to nausea in drivers. For those unaware, regenerative braking is a system where the vehicle's kinetic energy is generated automatically through the action of braking, and routed back into the battery as usable power. Regenerative braking can cause motion sickness for EV drivers, especially for those who have the EVs set for max regenerative braking, or for those using one-pedal mode, as the act of simply lifting off the accelerator would cause the car to slow down dramatically. For drivers, it can feel like the car is slowing down when they haven't prepared for it, and throw off their balance. 'Better knowledge on self-motion allows us to anticipate motion forces, which is crucial for motion sickness,' Emond explained to The Guardian. 'Yet, when the motion forces as estimated or anticipated by the brain differ from what actually is experienced, then the brain interprets this 'neural mismatch' as a situation of conflict. 'If this conflict persists over time, it may surpass a threshold for triggering autonomic reactions of the body such as symptoms apparent to 'motion sickness'.' For those considering purchasing some new wheels, Australia's car market is undergoing one of its biggest shake-ups in decades, with some experts calling it the most dramatic shift in automotive history. Australia has become a viable market for Chinese car manufacturers which has lead to aggressive local pricing, especially from brands such as BYD, Chery and GWM. data services Director Ross Booth said much of the automotive growth is coming from electric and electrified vehicles. 'We're seeing a clear shift towards more fuel-efficient vehicles, with strong growth in New Energy Vehicles – which include hybrids, plug-in hybrids, and battery electric vehicles,' Mr Booth said. Hybrid and electric vehicle sales made up just 8 per cent of new cars in 2021, jumping to 25 per cent by the end of 2025.
News.com.au
12 hours ago
- News.com.au
Health Check: And the EOFY biotech winner is … gasp … a pot stock
Bioxyne stars with a 720% gain in the 2024-25 year Paradigm shares soar 34% after $41 million convertible note deal Biotechs turn to debt funding The ASX biotech sector's best EOFY performer has come from left field: the local and European focused medicinal cannabis supplier Bioxyne (ASX:BXN). According to the Health Check Biotech Pulse – trademark pending – Bioxyne shares soared 720% in 2024-25, leaving its largely poorly performing pot peers in the dust. Bioxyne's fortunes have been driven by its Breathe Life Sciences arm, which purveys cannabis products including not just flowers and oils but pastilles, vapes, pessaries and suppositories (we kid you not). The company recently upgraded full-year revenue guidance from $25 to $28 million and promised positive cash flow and – gasp! – profitability. Amplia (ASX:ATX) took second place, with a 233% gain (300% over the last month). The stock soared after Amplia unveiled clinical trial results showing two 'complete responses' among a cohort of advanced pancreatic cancer patients. Orthocell (ASX:OCC) shares vaulted 220% on the back of US Food & Drug (FDA) approval of its novel nerve repair tool Remplir. Imricor Medical Systems (ASX:IMR) shares ended the year 189% to the good, as the company eyes FDA approval of its world's first MRI-guided ablation catheter. Other triple digit dazzlers were myelofibrosis drug developer Syntara (ASX:SNT) (up 130%), autism testing device play Blinklab (ASX:BB1) (up 116%) and the beloved radiology imaging tearaway ProMedicus (ASX:PME) (up 110%). Sorry – there's no prize for trying Sadly, there's still too much red ink in the rankings. In your columnist's opinion, investors have marked down many worthy stocks unfairly. But we're not in primary school and everyone doesn't get a ribbon for trying, so the record books will show that medication compliance group MedAdvisor (ASX:MDR) led the falls with an 82% decline. Other laggards are the multi-pronged Universal Biosensors (ASX:UBI) (down 76%), Proteomics International Laboratories (ASX:PIQ) (down 62%, see below), lung imager 4D Medical (ASX:4DX) (down 56%) and Clarity Pharmaceuticals (ASX:CU6) (down 51%). Shares in the busy Clarity shares peaked at $8.74 last October – a 70% gain for the year – but even after the subsequent sell off the company still bears an $800 million market cap. Strictly speaking, Opthea shares fared the worst after the company's infamous eye disease trail failure in March. Opthea shares never resumed trading, so the official records show a 73% gain when in fact the stock is worth next to nothing. Genetic Technologies and Nuheara are also missing from the laggards list, only because they went into administration and subsequently de-listed. Paradigm shifts to convertible notes With the equity capital raising outlook still looking shaky, Paradigm Biopharmaceuticals (ASX:PAR) has become the latest in a string of biotechs to tap alternative funding sources. The developer of a knee osteoarthritis (OA) drug candidate has tapped US$27 million ($41.2 million), by way of convertible notes. These have been issued to New York based alternative funder Obsidian Global Partners. Under the terms, Paradigm will draw an initial US$7 million to fund patient recruitment, trial operations and regulatory milestones. The balance of the facility is available at Paradigm's discretion, 'offering operational flexibility and strategic control over future funding needs'. Barring default, the notes are interest free. The cash will help to fund Paradigm's pivotal phase III trial of its repurposed drug candidate pentosan polysulphate sodium (PPS, or Zilosul). Investors have keenly awaited this trial initiation – and confirmation of how it will be funded. Reflecting this, Paradigm shares this morning surged 34%. The 466-patient study in underway across up to 15 Australian and 50 US sites. The company says it is now fully funded up to the interim analysis of the first 50% of patients, due in mid 2026. Last week Paradigm hedged its bets by paying as much as $16.5 million for Proteobioactives Pty Ltd ($500,000 upfront) This company owns an early-stage oral candidate for minor to mild OA, which combines PPS with a COX-2 inhibitor (Coxib). When debt is not a dirty word The term 'debt' can have unfortunate connotations – especially in the context of your columnist's household budget. But it can be cheaper than equity and has the benefit of being non-dilutive and more flexible with the timing of drawdowns. Often, it's simply more accessible than equity. The developer of better working anti-infectives, Recce Pharmaceuticals (ASX:RCE) last month availed of a US$20 million ($30 million) draw-down facility from the New York based Avenue Capital Group. Recce pockets an initial US$7.5 million and a further US$5 million between April and September this year. The remainder is available in calendar 2027, with all the amounts subject to 12.75% interest. The funds will support Recce's two phase III registrational studies on diabetic foot infections and acute bacterial skin and skin structure infections. Recce also recently raised $15.8 million of equity. Last month, dermatology group Botanix Pharmaceuticals (ASX:BOT) unveiled a circa US$30 million ($48 million) debt facility with Kreos Capital. Kreos is an arm of the world's biggest investment manager Blackrock. The facility provides for circa $US20 million to be drawn now, with the remainder to be tapped by October 2026 at the company's option. Under certain conditions, Kreos Capital can convert 20 percent of the loan into Botanix shares, at 33 cents apiece. Botanix developed Sofdra, a treatment for excessive underarm sweating and has started selling the product in the US. In mid-April Botanix also raised $40 million of equity, via an institutional placement. Proteomics secures non-dilutive $6 million Then there's non-dilutive grant funding. The Perth-based Proteomics today said it had secured a $6 million investment from the federally funded Bioplatforms Australia and the WA government. The funding will support developing an accredited protein biomarker analysis platform, in partnership with the University of Western Australia. Proteomics chips in $1 million over the three-year funding period. Proteomics has commercialised a predictive test for diabetic kidney disease and is developing assays for endometriosis, esophageal cancer and oxidative stress. Meso-blast off for FDA application? Stem-cell drug developer Mesoblast (ASX:MSB) says the company and the FDA are 'aligned' on what the company needs to do before it lodges a US marketing application for its heart disease candidate, Revascor. In late December Mesoblast won FDA approval for its childhood graft-versus-host disease (GvHD) candidate. This followed years of the company and the agency being decidedly 'unaligned'. Given the heart disease heart indication is much bigger than GvHD, today's news is more significant than it may appear at first blush. Mesoblast intends to file for accelerated approval by the end of the year. This is to treat ischemic heart failure patients with reduced ejection fraction and inflammation.
